| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10007053 | HBV | ENSG00000128052.10 | protein_coding | KDR | Yes | No | 3791 | P35968 |
| TVIS10007054 | HBV | ENSG00000128052.10 | protein_coding | KDR | Yes | No | 3791 | P35968 |
| TVIS10016656 | HBV | ENSG00000128052.10 | protein_coding | KDR | Yes | No | 3791 | P35968 |
| TVIS10000123 | HBV | ENSG00000128052.10 | protein_coding | KDR | Yes | No | 3791 | P35968 |
| TVIS20058066 | HPV | ENSG00000128052.10 | protein_coding | KDR | Yes | No | 3791 | P35968 |
| TVIS44025335 | HTLV-1 | ENSG00000128052.10 | protein_coding | KDR | Yes | No | 3791 | P35968 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | KDR |
|---|---|
| DrugBank ID | DB00398 |
| Drug Name | Sorafenib |
| Target ID | BE0000369 |
| UniProt ID | P35968 |
| Regulation Type | inhibitor |
| PubMed IDs | 16418310; 16446323; 16503817; 16757355; 16824050; 20586710 |
| Citations | Schoffski P, Dumez H, Clement P, Hoeben A, Prenen H, Wolter P, Joniau S, Roskams T, Van Poppel H: Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Ann Oncol. 2006 Aug;17(8):1185-96. Epub 2006 Jan 17.@@Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR, O'Dwyer PJ: Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol. 2006 Mar 20;24(9):1363-9. Epub 2006 Jan 30.@@Rini BI: Sorafenib. Expert Opin Pharmacother. 2006 Mar;7(4):453-61.@@Adnane L, Trail PA, Taylor I, Wilhelm SM: Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 2006;407:597-612.@@Lacouture ME, Desai A, Soltani K, Petronic-Rosic V, Laumann AE, Ratain MJ, Stadler WM: Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol. 2006 Nov;31(6):783-5. Epub 2006 Jul 4.@@Iyer R, Fetterly G, Lugade A, Thanavala Y: Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother. 2010 Aug;11(11):1943-55. doi: 10.1517/14656566.2010.496453. |
| Groups | Approved; Investigational |
| Direct Classification | Diarylethers |
| SMILES | CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1 |
| Pathways | Sorafenib Metabolism Pathway |
| PharmGKB | PA7000 |
| ChEMBL | CHEMBL1336 |
